Company
PepGen
Developing a new generation of disease-modifying therapies.
- Business model
- B2B
- Legal name
- PepGen, Inc.
Claim, correct or request removal
Record updated 28 September 2026
About
At PepGen, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic neuromuscular and neurological diseases.
Funding snapshot
- Total raised
- $127MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $112M2021-07-30
Funding rounds
- Round, 2021
- $112M2021-07-30, SEC form D sold, 15 investors
- Round, 2020
- $14.4M2020-11-24, SEC form D sold, 6 investors
Products
- Enhanced Delivery Oligonucleotide (EDO) platform
- PGN-EDODM1
Loading relationship preview